Literature DB >> 21156798

Efficient in vivo manipulation of alternative pre-mRNA splicing events using antisense morpholinos in mice.

Marilyn K Parra1, Sherry Gee, Narla Mohandas, John G Conboy.   

Abstract

Mammalian pre-mRNA alternative splicing mechanisms are typically studied using artificial minigenes in cultured cells, conditions that may not accurately reflect the physiological context of either the pre-mRNA or the splicing machinery. Here, we describe a strategy to investigate splicing of normal endogenous full-length pre-mRNAs under physiological conditions in live mice. This approach employs antisense vivo-morpholinos (vMOs) to mask cis-regulatory sequences or to disrupt splicing factor expression, allowing functional evaluation of splicing regulation in vivo. We applied this strategy to gain mechanistic insight into alternative splicing events involving exons 2 and 16 (E2 and E16) that control the structure and function of cytoskeletal protein 4.1R. In several mouse tissues, inclusion of E16 was substantially inhibited by interfering with a splicing enhancer mechanism using a target protector morpholino that blocked Fox2-dependent splicing enhancers in intron 16 or a splice-blocking morpholino that disrupted Fox2 expression directly. For E2, alternative 3'-splice site choice is coordinated with upstream promoter use across a long 5'-intron such that E1A splices almost exclusively to the distal acceptor (E2dis). vMOs were used to test the in vivo relevance of a deep intron element previously proposed to determine use of E2dis via a two-step intrasplicing model. Two independent vMOs designed against this intronic regulatory element inhibited intrasplicing, robustly switching E1A splicing to the proximal acceptor (E2prox). This finding strongly supports the in vivo physiological relevance of intrasplicing. vMOs represent a powerful tool for alternative splicing studies in vivo and may facilitate exploration of alternative splicing networks in vivo.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21156798      PMCID: PMC3057813          DOI: 10.1074/jbc.M110.158154

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

1.  Alternative pre-mRNA splicing switches modulate gene expression in late erythropoiesis.

Authors:  Miki L Yamamoto; Tyson A Clark; Sherry L Gee; Jeong-Ah Kang; Anthony C Schweitzer; Amittha Wickrema; John G Conboy
Journal:  Blood       Date:  2009-02-04       Impact factor: 22.113

2.  Vivo-Morpholinos: a non-peptide transporter delivers Morpholinos into a wide array of mouse tissues.

Authors:  Paul A Morcos; Yongfu Li; Shan Jiang
Journal:  Biotechniques       Date:  2008-12       Impact factor: 1.993

3.  Cancer-associated regulation of alternative splicing.

Authors:  Julian P Venables; Roscoe Klinck; ChuShin Koh; Julien Gervais-Bird; Anne Bramard; Lyna Inkel; Mathieu Durand; Sonia Couture; Ulrike Froehlich; Elvy Lapointe; Jean-François Lucier; Philippe Thibault; Claudine Rancourt; Karine Tremblay; Panagiotis Prinos; Benoit Chabot; Sherif Abou Elela
Journal:  Nat Struct Mol Biol       Date:  2009-05-17       Impact factor: 15.369

4.  Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice.

Authors:  Bo Wu; Yongfu Li; Paul A Morcos; Timothy J Doran; Peijuan Lu; Qi Long Lu
Journal:  Mol Ther       Date:  2009-03-10       Impact factor: 11.454

5.  Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy.

Authors:  Jason H Williams; Rebecca C Schray; Carlyn A Patterson; Semira O Ayitey; Melanie K Tallent; Gordon J Lutz
Journal:  J Neurosci       Date:  2009-06-17       Impact factor: 6.167

6.  Long-term improvement in mdx cardiomyopathy after therapy with peptide-conjugated morpholino oligomers.

Authors:  Natee Jearawiriyapaisarn; Hong M Moulton; Peter Sazani; Ryszard Kole; Monte S Willis
Journal:  Cardiovasc Res       Date:  2009-10-08       Impact factor: 10.787

7.  A short antisense oligonucleotide masking a unique intronic motif prevents skipping of a critical exon in spinal muscular atrophy.

Authors:  Natalia N Singh; Maria Shishimorova; Lu Cheng Cao; Laxman Gangwani; Ravindra N Singh
Journal:  RNA Biol       Date:  2009-07-14       Impact factor: 4.652

8.  Autoregulation of Fox protein expression to produce dominant negative splicing factors.

Authors:  Andrey Damianov; Douglas L Black
Journal:  RNA       Date:  2009-12-30       Impact factor: 4.942

9.  Coupled transcription-splicing regulation of mutually exclusive splicing events at the 5' exons of protein 4.1R gene.

Authors:  Shu-Ching Huang; Aeri Cho; Stephanie Norton; Eva S Liu; Jennie Park; Anyu Zhou; Indira D Munagala; Alexander C Ou; Guang Yang; Amittha Wickrema; Tang K Tang; Edward J Benz
Journal:  Blood       Date:  2009-09-03       Impact factor: 22.113

Review 10.  RNA and disease.

Authors:  Thomas A Cooper; Lili Wan; Gideon Dreyfuss
Journal:  Cell       Date:  2009-02-20       Impact factor: 41.582

View more
  16 in total

Review 1.  Shielding the messenger (RNA): microRNA-based anticancer therapies.

Authors:  Elena Sotillo; Andrei Thomas-Tikhonenko
Journal:  Pharmacol Ther       Date:  2011-04-14       Impact factor: 12.310

2.  Deep intron elements mediate nested splicing events at consecutive AG dinucleotides to regulate alternative 3' splice site choice in vertebrate 4.1 genes.

Authors:  Marilyn K Parra; Thomas L Gallagher; Sharon L Amacher; Narla Mohandas; John G Conboy
Journal:  Mol Cell Biol       Date:  2012-04-02       Impact factor: 4.272

Review 3.  Antisense mediated splicing modulation for inherited metabolic diseases: challenges for delivery.

Authors:  Belen Pérez; Lluisa Vilageliu; Daniel Grinberg; Lourdes R Desviat
Journal:  Nucleic Acid Ther       Date:  2014-02       Impact factor: 5.486

4.  Rbfox-regulated alternative splicing is critical for zebrafish cardiac and skeletal muscle functions.

Authors:  Thomas L Gallagher; Joshua A Arribere; Paul A Geurts; Cameron R T Exner; Kent L McDonald; Kariena K Dill; Henry L Marr; Shaunak S Adkar; Aaron T Garnett; Sharon L Amacher; John G Conboy
Journal:  Dev Biol       Date:  2011-09-07       Impact factor: 3.582

5.  Use of vivo-morpholinos for control of protein expression in the adult rat brain.

Authors:  Kathryn J Reissner; Gregory C Sartor; Elena M Vazey; Thomas E Dunn; Gary Aston-Jones; Peter W Kalivas
Journal:  J Neurosci Methods       Date:  2011-10-17       Impact factor: 2.390

6.  Rbfox proteins regulate alternative mRNA splicing through evolutionarily conserved RNA bridges.

Authors:  Michael T Lovci; Dana Ghanem; Henry Marr; Justin Arnold; Sherry Gee; Marilyn Parra; Tiffany Y Liang; Thomas J Stark; Lauren T Gehman; Shawn Hoon; Katlin B Massirer; Gabriel A Pratt; Douglas L Black; Joe W Gray; John G Conboy; Gene W Yeo
Journal:  Nat Struct Mol Biol       Date:  2013-11-10       Impact factor: 15.369

7.  Lessons learned from vivo-morpholinos: How to avoid vivo-morpholino toxicity.

Authors:  David P Ferguson; Lawrence J Dangott; J Timothy Lightfoot
Journal:  Biotechniques       Date:  2014-05-01       Impact factor: 1.993

8.  Directed Alternative Splicing in Nijmegen Breakage Syndrome: Proof of Principle Concerning Its Therapeutical Application.

Authors:  Bastian Salewsky; Gabriele Hildebrand; Susanne Rothe; Ann Christin Parplys; Janina Radszewski; Moritz Kieslich; Petra Wessendorf; Harald Krenzlin; Kerstin Borgmann; André Nussenzweig; Karl Sperling; Martin Digweed
Journal:  Mol Ther       Date:  2015-08-12       Impact factor: 11.454

9.  A functional splice variant of the human Golgi CMP-sialic acid transporter.

Authors:  Roberta Salinas-Marín; Rosella Mollicone; Iván Martínez-Duncker
Journal:  Glycoconj J       Date:  2016-07-07       Impact factor: 2.916

10.  Vivo-morpholinos induced transient knockdown of physical activity related proteins.

Authors:  David P Ferguson; Emily E Schmitt; J Timothy Lightfoot
Journal:  PLoS One       Date:  2013-04-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.